摘要
目的探讨小眼畸形相关转录因子(MITF)基因扩增对重组人血管内皮抑素(恩度)联合达卡巴嗪一线治疗晚期黑色素瘤的疗效预测作用。方法收集60例接受恩度联合达卡巴嗪一线治疗晚期黑色素瘤患者的石蜡包埋组织样本,采用实时定量PCR检测MITF基因扩增,观察患者的疾病控制率和远期疗效。结果 56例晚期黑色素瘤样本成功检测,MITF基因扩增率为51.8%(29/56),其中肢端、非肢端皮肤、黏膜、原发不明黑色素瘤中的MITF基因扩增率分别为31.2%、63.2%、80.0%和36.4%(P=0.050)。MITF基因扩增组与无扩增组患者接受恩度联合达卡巴嗪治疗的疾病控制率分别为58.6%(17/29)和81.5%(22/27),差异无统计学意义(P=0.063);两组的中位无进展生存期分别为6.4个月(95%CI:0.5～12.2个月)和8.4个月(95%CI:6.8～10.3个月),差异亦无统计学意义(P=0.169)。结论中国晚期黑色素瘤患者MITF基因扩增率较高,检测MITF基因扩增可能有助于预测恩度联合达卡巴嗪治疗晚期黑色素瘤的疗效,总生存结果有待进一步随访。
Objective To investigate the predictive effect of microphthalmia-associated transcription factor（MITF） gene am- plification on clinical outcome of recombined human endostatin（endostar） plus dacarbazine as first-line treatment for patients with me- tastatic melanoma. Methods MITF gene amplification in tumor tissues obtained from 60 metastatic melanoma patients were deter- mined by quantitative real-time PCR. All the patients were followed for disease control rate and long-term efficacy. Results Of 60 tumor tissues, 56 were evaluable for MITF gene detection. MITF gene amplification was detected in 29 of 56 patients（51.8% ）, 31.2% （5/16） of acral, 63.2% （12/19） of non-acral, 80.0% （8/10） of mucosal and 36. 4% （4/11 ） of unknown primary melanoma （P =0. 050）. The disease control rate of patients with or without MITF gene amplification were 58.6% and 81.5% （P =0. 063） ; and the median time to progression were 6.4 months（95% C1：0. 5-12. 2 months） and 8.4 months（95% C1：6. 8-10. 3 months） ,respectively （P = 0. 169）. Conclusion MITF gene amplification rate of Chinese metastatic melanoma is high. It seems to have potential to predict the efficacy of endostar plus dacarbazine in treatment of metastatic melanoma. Further survival data needs long-term follow-up.
出处
《临床肿瘤学杂志》
CAS
2013年第6期494-497,共4页
Chinese Clinical Oncology
基金
国家自然科学基金资助项目(81172196
81102068)
北京市科技新星计划资助项目(2012035)
